Hemispherx Biopharma, Inc.
HEB announced that at the Options for the Control of Influenza VIII
Conference in Cape Town, South Africa held 5-10 September, 2013, that a
scientific advisor to Hemispherx, Professor Dr. Juergen A. Richt, DVM, Ph.D.,
Director of the U.S. Department of Homeland Security Center of Excellence for
Emerging and Zoonotic Animal Diseases (CEEZAD), Regents Distinguished
Professor at Kansas State University, and an Eminent Scholar of Kansas
Bioscience Association (KBA), described his experiments in human lung cells
evidencing that Alferon N Injection^®, the only multi-species, natural
interferon approved in the U.S. for the treatment of human refractory HPV
genital warts, is biologically active, in low doses, against various classes
of viruses occurring naturally in animals and humans.
The increasing prevalence of oseltamivir-resistant Influenza A viruses (IAVs),
particularly H7N9, has been widely reported and is due in large part to the
fact that just a single-step mutation in the neuraminidase (NA) gene of this
genetically unstable virus makes it resistant to oseltamivir (Tamiflu^®). Dr.
Richt reported on influenza genome instability "Viral reassortment and
transmission after co-infection of pigs with classical H1N1 and
triple-reassortant H3N2 swine influenza viruses" in 2010 in the peer-reviewed
Journal of General Virology, an international journal.
The results of the recent Kansas State University experiments, coupled with
Dr. Richt's work on reassortment and other published studies, set the stage
for evaluating the possibility that mutational changes and reassortment could
be prevented in animals by the use of type I interferon and/or a type I
interferon inducer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in